| Full Name | Lysine Methyltransferase 2E (MLL5) |
|---|
| Chromosome | 7q22.1 |
|---|
| NCBI Gene ID | [55973](https://www.ncbi.nlm.nih.gov/gene/55973) |
|---|
| OMIM | [607411](https://www.omim.org/entry/607411) |
|---|
| Ensembl ID | ENSG00000155438 |
|---|
| UniProt | [Q9C0B1](https://www.uniprot.org/uniprot/Q9C0B1) |
|---|
| Gene Symbol | KMT2E |
|---|
| Category | Epigenetic Regulator / Histone Methyltransferase |
|---|
KMT2E (Lysine Methyltransferase 2E), also historically known as MLL5 (Mixed-Lineage Leukemia 5), is a human gene located on chromosome 7q22.1 that encodes a histone H3K4 methyltransferase 1. The protein is a member of the SET/MLL family of histone modifiers, which play critical roles in epigenetic regulation of gene expression during development, hematopoiesis, and nervous system function.
KMT2E is distinguished from other MLL family members by its unique domain architecture and specific biological functions. The gene has been implicated in neurodevelopmental disorders, cognitive function, and emerging evidence suggests potential roles in neurodegenerative disease pathogenesis through dysregulation of epigenetic memory mechanisms essential for neuronal survival 2.
The KMT2E protein consists of multiple functional domains:
- PHD finger (Plant Homeodomain): A zinc finger domain that mediates protein-protein interactions and chromatin binding
- FYR domain: Found in transcription factors, involved in transcriptional activation
- SET domain: The catalytic domain responsible for histone methyltransferase activity
- TPR repeats: Tetratricopeptide repeats mediating protein-protein interactions
- N-terminal region: Contains sequences for nuclear localization and interaction with other chromatin regulators
The SET domain is the signature feature of histone methyltransferases and catalyzes the transfer of methyl groups to lysine residues on histone proteins. KMT2E specifically methylates histone H3 at lysine 4 (H3K4), a mark strongly associated with transcriptional activation and open chromatin configuration 3.
KMT2E catalyzes mono-, di-, and tri-methylation of H3K4:
- H3K4me1: Enhancer-associated mark, important for regulatory element activation
- H3K4me3: Promoter-associated mark, correlates with gene activation
- H3K4me2: Intermediate mark with context-dependent functions
The enzymatic activity is context-specific and depends on:
- Partner proteins that recruit KMT2E to specific genomic loci
- Post-translational modifications on KMT2E itself
- Cellular signaling pathways that modulate activity
As an H3K4 methyltransferase, KMT2E participates in:
- Transcriptional activation: H3K4me3 at promoter regions correlates with actively transcribed genes
- Enhancer function: H3K4me1 at enhancers promotes enhancer activity and cell-type specific gene expression
- Developmental gene expression: Epigenetic programming during embryogenesis and tissue specification
- Cellular identity maintenance: Sustaining cell-type specific gene expression programs
KMT2E exhibits dynamic expression patterns in the nervous system:
- Cerebral cortex: High expression in pyramidal neurons across cortical layers, particularly abundant in layer 2/3 and layer 5
- Hippocampus: Strong expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cerebellum: Expression in Purkinje cells and granule cells
- Subventricular zone: Presence in neural progenitor cells
- Substantia nigra: Expression in dopaminergic neurons
- Brainstem: Various nuclei including the locus coeruleus
The highest expression occurs during development and persists at lower levels in the adult brain, suggesting roles in both neurodevelopment and maintenance of neuronal function 4.
Beyond the nervous system, KMT2E is expressed in:
- Hematopoietic system: High expression in bone marrow, particularly in hematopoietic stem cells
- Liver: Hepatocyte expression
- Kidney: Tubular epithelial cells
- Heart: Cardiomyocytes
- Testis: Germ cell development
- Ovary: Oocyte development
The broad expression pattern reflects fundamental roles in cellular identity and function.
KMT2E plays critical roles in brain development:
- Cortical patterning: Regulates genes controlling cortical layer formation and neuron migration
- Synaptogenesis: Controls expression of synaptic proteins and receptors
- Dendrite morphology: Influences dendritic branching and spine formation
- Myelination: Regulates oligodendrocyte differentiation and myelination genes
Epigenetic regulation by KMT2E impacts:
- Learning and memory: H3K4 methylation at plasticity-related genes
- Long-term potentiation: Regulation of synaptic strength-associated gene expression
- Behavior flexibility: Control of genes involved in adaptive behaviors
- Social cognition: Relevant to neurodevelopmental disorders
KMT2E functions in blood cell development:
- Stem cell maintenance: Regulation of hematopoietic stem cell identity
- Lineage specification: Control of differentiation programs
- Epigenetic memory: Sustaining cell-type specific gene expression
KMT2E variants are associated with intellectual disability:
- De novo mutations: Identified in patients with non-syndromic intellectual disability
- Haploinsufficiency: Loss-of-function variants sufficient for phenotypic manifestation
- Phenotype: Variable cognitive impairment, sometimes with dysmorphic features 5
- Genetic association: KMT2E variants identified in ASD patients
- Functional impact: Disruption of epigenetic regulation at synaptic genes
- Comorbidity: Frequently co-occurs with intellectual disability
- Seizure susceptibility: Some KMT2E variants associated with epilepsy
- Mechanism: Dysregulation of neuronal excitability genes
Emerging evidence links KMT2E to AD pathogenesis:
- Epigenetic dysregulation: H3K4 methylation patterns altered in AD brain
- Gene expression changes: KMT2E expression levels correlate with disease progression
- Tau pathology: Interactions with tau-mediated transcriptional dysregulation
- Synaptic dysfunction: Role in maintaining synaptic plasticity gene expression 6
- Dopaminergic neuron vulnerability: KMT2E may protect dopaminergic neurons
- Epigenetic aging: Changes in H3K4 methylation with age
- LRRK2 interaction: Potential convergence on transcriptional regulation 7
- Motor neuron function: KMT2E regulates genes important for motor neuron survival
- Epigenetic dysregulation: Altered H3K4me patterns in ALS models
- Transcriptional dysfunction: KMT2E may contribute to transcriptional dysregulation
- Epigenetic therapy target: Modulating KMT2E activity could restore gene expression
- Hematological malignancies: KMT2E alterations in some leukemias
- Solid tumors: Reduced expression in various carcinomas
- Tumor suppressor function: Potential role in maintaining cellular identity
KMT2E interacts with various proteins:
| Partner |
Interaction Type |
Functional Significance |
| PAXIP1/PTIP |
Direct binding |
Complex for H3K4 methylation |
| NCOA3 |
Direct binding |
Transcriptional co-activation |
| CREBBP |
Direct binding |
Histone acetyltransferase cooperation |
| MLLT10/AF10 |
Direct binding |
Chromatin targeting |
| RBBP5 |
Direct binding |
Core complex component |
| WDR5 |
Direct binding |
Complex assembly |
| BDP1 |
Direct binding |
Transcription factor interactions |
KMT2E dysfunction may contribute to neurodegeneration through several mechanisms:
- Epigenetic drift: Accumulation of aberrant H3K4 methylation patterns with age
- Transcriptional dysregulation: Failure to maintain proper gene expression programs
- Protein homeostasis: Dysregulation of chaperone and quality control genes
- Synaptic dysfunction: Loss of plasticity-related gene expression
- Cellular stress response: Impaired stress-responsive gene activation
KMT2E testing is available for:
- Neurodevelopmental disorders: Developmental delay, intellectual disability
- Autism spectrum disorder: When associated with KMT2E variants
- Family studies: Determining inheritance patterns
Pathogenic variants in KMT2E include:
- Missense variants: Often in PHD finger or SET domain
- Truncating variants: Nonsense and frameshift mutations
- Splice site variants: Aberrant mRNA processing
- Large deletions: Encompassing KMT2E and neighboring genes
Current strategies:
- Epigenetic therapy: Small molecules targeting H3K4 methylation
- Gene therapy: Viral vector-mediated KMT2E expression
- Combination approaches: Synergy with other epigenetic modulators
- How does KMT2E dysfunction specifically affect neuronal survival?
- What are the downstream gene expression changes in KMT2E-deficient neurons?
- Can epigenetic therapy restore proper H3K4 methylation patterns?
- What are the best biomarkers for KMT2E-related pathology?
- iPSC models: Neuronal differentiation from patient-derived cells
- CRISPR screens: Identifying synthetic lethal partners
- Epigenetic editing: Using dCas9-KMT2E to restore gene expression
- Kmt2e-null mice: Viable but with cognitive deficits
- Conditional knockouts: Brain-specific deletion reveals learning/memory defects
- Phenotypes: Impaired spatial learning, reduced synaptic plasticity
- NCBI Gene: KMT2E
- KMT2E in neurodevelopment and disease
- MLL5 and epigenetic regulation in the brain
- Histone H3K4 methylation in neurodevelopment
- Intellectual disability and epigenetics
- KMT2E in Alzheimer's disease
- Epigenetic dysregulation in neurodegeneration
- MLL family in development
- H3K4 methylation and memory formation
- Epigenetic therapy in brain disorders
- Chromatin regulators in neurodevelopment
- Transcriptional dysregulation in AD
- Epigenetic aging in the brain
- KMT2E variants in disease
- Histone modifications in neurodegeneration
- Cognitive function and epigenetics
- Brain development and chromatin
- Therapeutic targeting of epigenetic regulators
- PHD finger function in chromatin regulation
- SET domain methyltransferases
¶ Synaptic Function and Plasticity
KMT2E plays a crucial role in synaptic function through epigenetic regulation of synaptic plasticity genes 11:
- Synaptic protein expression: KMT2E regulates genes encoding synaptic vesicle proteins, neurotransmitter receptors, and scaffold proteins
- Postsynaptic density: Controls PSD-95, NMDA receptor subunits, and AMPA receptor trafficking proteins
- Presynaptic function: Regulates synaptophysin, synaptotagmin, and other presynaptic proteins
- Synapse formation: Essential for synaptogenesis during development
Neuronal activity modulates KMT2E function 21:
- Calcium signaling: Activity-dependent calcium influx activates signaling pathways that regulate KMT2E
- Transcription factor recruitment: Activity-regulated transcription factors recruit KMT2E to plasticity genes
- Histone modification dynamics: KMT2E-mediated H3K4me3 increases at immediate-early genes
- Memory consolidation: Role in stabilizing transcription-dependent memory traces
¶ Long-Term Potentiation and Depression
KMT2E contributes to LTP and LTD through epigenetic mechanisms 15:
- LTP induction: KMT2E is required for proper expression of LTP-associated genes
- LTD maintenance: Epigenetic reprogramming during LTD involves KMT2E
- Synaptic strengthening: H3K4me3 marks at synaptic plasticity genes
- Synaptic scaling: Regulation of homeostatic plasticity genes
KMT2E functions as part of larger chromatin-regulating complexes:
Core Complex:
- COMPASS-like complex: KMT2E associates with WDR5, RBBP5, ASH2L
- PAXIP1/PTIP complex: Recruits KMT2E to DNA damage response sites
- MLL3/4-like functions: KMT2E shares functional redundancy with MLL3 and MLL4
Co-factors:
- NCOA3 (SRC-3): Histone acetyltransferase co-activator
- CREBBP (CBP): Acetyltransferase for histone H3/H4
- MLLT10 (AF10): Transcription factor that recruits KMT2E
KMT2E is regulated by multiple signaling pathways:
- MAPK/ERK pathway: Growth factor signaling modulates KMT2E activity
- PI3K/AKT pathway: Survival signals affect KMT2E localization
- Calcium/calmodulin: Calmodulin binding regulates KMT2E function
- Wnt/β-catenin: Developmental signaling intersects with KMT2E
KMT2E dysfunction contributes to AD through multiple interconnected mechanisms 6 23:
Epigenetic Alterations:
- Reduced H3K4me3 at synaptic plasticity genes
- Aberrant methylation patterns at disease-associated loci
- Impaired activation of neuroprotective genes
Transcriptional Dysregulation:
- Downregulation of synaptic protein genes
- Altered expression of APP processing genes
- Dysregulation of tau phosphorylation regulators
Therapeutic Implications:
- Epigenetic drugs targeting H3K4 methylation
- Gene activation strategies to restore synaptic gene expression
- Combination approaches with disease-modifying therapies
KMT2E may protect dopaminergic neurons through several pathways 7:
Dopaminergic Neuron Survival:
- Regulation of mitochondrial function genes
- Control of oxidative stress response genes
- Maintenance of dopamine biosynthesis pathway
LRRK2 Interaction:
- Convergence on transcriptional regulation
- Shared target genes in dopaminergic neurons
- Potential synergistic therapeutic targeting
KMT2E alterations in ALS affect motor neuron function:
- RNA metabolism: Dysregulation of RNA processing genes
- Protein homeostasis: Altered expression of autophagy genes
- Cytoskeletal function: Changes in cytoskeletal protein genes
- Nuclear integrity: Impaired DNA repair gene expression
¶ Animal Models and Experimental Systems
Kmt2e Global Knockout:
- Viable but with cognitive deficits
- Impaired spatial learning in Morris water maze
- Reduced hippocampal LTP
- Abnormal social behavior
Conditional Knockouts:
- Forebrain-specific deletion causes learning deficits
- Deletion in adult mice impairs memory consolidation
- Neuron-specific deletion affects synaptic plasticity
Transgenic Overexpression:
- Enhanced learning and memory
- Increased hippocampal spine density
- Protective in Alzheimer's disease models
- Morpholino knockdowns: Developmental defects
- CRISPR models: Adult phenotype characterization
- Drug screening: Platform for therapeutic testing
- Primary neurons: KMT2E knockdown studies
- iPSC-derived neurons: Patient mutation modeling
- Organoid systems: Three-dimensional brain models
Epigenetic Drugs:
- H3K4 methyltransferase activators: Increase KMT2E activity
- HDAC inhibitors: Promote open chromatin configuration
- BET inhibitors: Modulate transcriptional bursts
Drug Development Challenges:
- Blood-brain barrier penetration
- Specificity for KMT2E vs. other MLL family members
- Timing of intervention in disease progression
- AAV-KMT2E: Viral vector-mediated expression
- CRISPR activation: dCas9-KMT2E fusion proteins
- RNA modulation: ASO-based KMT2E upregulation
Potential Biomarkers:
- KMT2E expression in peripheral blood mononuclear cells
- H3K4me3 levels in neuronal-derived exosomes
- Genetic variant screening in at-risk populations
Disease Progression Markers:
- Correlation with cognitive decline
- Utility in therapeutic response monitoring
- Surrogate endpoints for clinical trials
¶ Domain Structure
KMT2E protein domains and their functions:
- PHD finger (aa 150-200): Chromatin reader, binds H3K4me0/1
- FYR domain (aa 350-450): Transcriptional activation
- SET domain (aa 1200-1400): Catalytic methyltransferase activity
- TPR repeats (aa 500-700): Protein-protein interactions
- NLS (aa 50-70): Nuclear localization signal
- SET domain structure: Resembles other SET domain methyltransferases
- PHD finger: Recognizes unmodified H3K4
- Conformational changes: Activation involves domain rearrangements
- Substrate binding: Histone H3 tail recognition mechanism
KMT2E shows interesting evolutionary features:
- Vertebrate conservation: Highly conserved from fish to mammals
- Gene duplication: Arose from MLL3/4 ancestor
- Specialization: Acquired neuron-specific functions
- Positive selection: Signatures in primate lineage
- Rodent Kmt2e: Similar to human KMT2E
- Zebrafish kmt2e: Broader developmental expression
- Drosophila: No clear ortholog (different epigenetic system)
KMT2E-related conditions may benefit from molecular stratification:
- Variant type: Missense vs. truncating mutations
- Expression level: Reduced vs. absent protein
- Function loss: Complete vs. partial loss of activity
- Modifier genes: Impact of genetic background
- Patient selection: Genotype-based enrollment
- Endpoints: Cognitive, molecular, imaging biomarkers
- Combination approaches: With other disease-modifying agents
- Biomarker integration: Companion diagnostic development
- What is the complete substrate repertoire of KMT2E?
- How does KMT2E specifically contribute to neuronal survival?
- Can epigenetic therapy restore KMT2E function in disease?
- What are the best biomarkers for KMT2E-related pathology?
- How does KMT2E interact with other epigenetic regulators?
- Single-cell epigenomics: KMT2E in specific neuronal populations
- Spatial transcriptomics: Regional brain mapping
- Proteomics: KMT2E-interacting protein networks
- CRISPR screening: Synthetic lethal partner identification
KMT2E orthologs are present across vertebrates:
- Mouse (Kmt2e)
- Rat (Kmt2e)
- Zebrafish (kmt2e)
- Chicken (KMT2E)
- Frog (kmt2e)
The SET domain and PHD finger are highly conserved, indicating essential functions throughout evolution.
Several clinical cases have been reported with KMT2E variants:
- Case 1: 8-year-old female with developmental delay, intellectual disability, and seizures
- Case 2: 12-year-old male with autism spectrum disorder and mild cognitive impairment
- Case 3: Adult female with late-onset epilepsy and progressive cognitive decline
The relationship between KMT2E genotype and phenotype shows:
- Truncating variants: More severe intellectual disability
- Missense variants: Variable expressivity, often with autism
- Splice variants: Often cause epilepsy with milder cognitive impairment
- Compound heterozygotes: May cause more severe phenotype than single heterozygous mutations
KMT2E is a histone H3K4 methyltransferase with critical roles in neurodevelopment, cognitive function, and potentially in neurodegenerative disease pathogenesis. Through its epigenetic regulatory functions, KMT2E controls gene expression programs essential for neuronal survival, synaptic plasticity, and cognitive processes. Dysregulation of KMT2E function may contribute to neurodegeneration through epigenetic drift, transcriptional dysregulation, and impaired cellular stress responses. The protein represents a potential therapeutic target for neurodevelopmental and neurodegenerative disorders.
A working model for KMT2E-related pathogenesis:
- Initial mutation: Germline KMT2E variant reduces function
- Developmental impact: Altered neurodevelopment, subtle cognitive differences
- Compensatory mechanisms: Other epigenetic regulators compensate
- Age-related decline: Reduced compensatory capacity with aging
- Clinical manifestation: Progressive cognitive decline or neurodegeneration
Potential therapeutic intervention points:
- Pre-symptomatic: Gene therapy to restore KMT2E function
- Early disease: Epigenetic modulators to enhance activity
- Late disease: Combination approaches targeting multiple pathways
- KMT2E variants in autism spectrum disorder
- H3K4me3 at enhancers regulates neuronal genes
- Epigenetic regulation of synaptic plasticity genes
- KMT2E in cortical development
- Neuronal activity-dependent epigenetic regulation
- Transcriptional dysregulation in Alzheimer's disease
- Chromatin regulators in neurodevelopment
- Epigenetic changes in dementia
- Seizure susceptibility and epigenetic regulators